New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

42

Novartis Inks $1.35 Billion Deal with Mesoblast for Remestemcel-L for Covid-19 ARDS

Novartis inked an exclusive worldwide license and collaboration deal with Australia-based Mesoblast to develop, commercialize and manufacture remestemcel-L for acute respiratory distress syndrome (ARDS), including when it is linked to Covid-19.

43

Covid-19 reinfection unlikely for at least six months, study finds

People who have had Covid-19 are highly unlikely to contract the disease again for at least six months after their first infection, according to a British study of healthcare workers on the frontline of the fight against the coronavirus pandemic.

46

FDA Grants EUA to Combination of Olumiant and Remdesivir in Hospitalized Covid-19 Patients

The U.S. Food and Drug Administration granted Emergency Use Authorization to a combination of Eli Lilly’s and Incyte’s rheumatoid arthritis drug Olumiant (baricitinib) and Gilead Sciences’ remdesivir as a treatment for hospitalized patients diagnosed with Covid-19 who require supplemental oxygen or ventilation.